606 related articles for article (PubMed ID: 26884885)
1. A three gene-based risk score predicts prognosis of resected non-small-cell lung cancer.
Liu K; Chen HL; Gu MM; You QS
Int J Clin Exp Pathol; 2015; 8(12):16081-8. PubMed ID: 26884885
[TBL] [Abstract][Full Text] [Related]
2. Relationship between NOB1 expression and prognosis of resected non-small cell lung cancer.
Liu K; Chen HL; Gu MM; You QS
Int J Biol Markers; 2015 Feb; 30(1):e43-8. PubMed ID: 25450647
[TBL] [Abstract][Full Text] [Related]
3. High expression of the transcriptional co-activator p300 predicts poor survival in resectable non-small cell lung cancers.
Hou X; Li Y; Luo RZ; Fu JH; He JH; Zhang LJ; Yang HX
Eur J Surg Oncol; 2012 Jun; 38(6):523-30. PubMed ID: 22440742
[TBL] [Abstract][Full Text] [Related]
4. NOB1 expression predicts early response to cisplatin-based chemotherapy in patients with advanced non-small cell lung cancer.
Liu K; Chen HL; Gu MM; You QS
J Chemother; 2016 Jun; 28(3):225-9. PubMed ID: 25971309
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancer.
Inoue Y; Yoshimura K; Kurabe N; Kahyo T; Kawase A; Tanahashi M; Ogawa H; Inui N; Funai K; Shinmura K; Niwa H; Suda T; Sugimura H
Oncotarget; 2017 Jan; 8(5):8738-8751. PubMed ID: 28060732
[TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of vascular invasion and standardization of its evaluation in stage I non-small cell lung cancer.
Hamanaka R; Yokose T; Sakuma Y; Tsuboi M; Ito H; Nakayama H; Yamada K; Masuda R; Iwazaki M
Diagn Pathol; 2015 Apr; 10():17. PubMed ID: 25884820
[TBL] [Abstract][Full Text] [Related]
7. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy.
Tokito T; Azuma K; Kawahara A; Ishii H; Yamada K; Matsuo N; Kinoshita T; Mizukami N; Ono H; Kage M; Hoshino T
Eur J Cancer; 2016 Mar; 55():7-14. PubMed ID: 26771872
[TBL] [Abstract][Full Text] [Related]
8. Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis.
Tang JM; He QY; Guo RX; Chang XJ
Lung Cancer; 2006 Feb; 51(2):181-91. PubMed ID: 16324768
[TBL] [Abstract][Full Text] [Related]
9. Expression of p63, TTF-1 and Maspin in Non-Small Cell Lung Carcinoma and Their Effect on the Prognosis and Differential Diagnosis.
Yaman B; Nart D; Ekren PK; Çok G; Veral A
Turk Patoloji Derg; 2015; 31(3):163-74. PubMed ID: 26456962
[TBL] [Abstract][Full Text] [Related]
10. Down-regulation of miR-503 expression predicate advanced mythological features and poor prognosis in patients with NSCLC.
Liu L; Qu W; Zhong Z
Int J Clin Exp Pathol; 2015; 8(5):5609-13. PubMed ID: 26191272
[TBL] [Abstract][Full Text] [Related]
11. Tumor angiogenesis in predicting the survival of patients with stage I lung cancer.
Medetoglu B; Gunluoglu MZ; Demir A; Melek H; Buyukpinarbasili N; Fener N; Dincer SI
J Thorac Cardiovasc Surg; 2010 Nov; 140(5):996-1000. PubMed ID: 20708755
[TBL] [Abstract][Full Text] [Related]
12. Lymphatic invasion predicts survival in patients with early node-negative non-small cell lung cancer.
Nentwich MF; Bohn BA; Uzunoglu FG; Reeh M; Quaas A; Grob TJ; Perez D; Kutup A; Bockhorn M; Izbicki JR; Vashist YK
J Thorac Cardiovasc Surg; 2013 Oct; 146(4):781-7. PubMed ID: 23778087
[TBL] [Abstract][Full Text] [Related]
13. Serum microRNA-365 in combination with its target gene TTF-1 as a non-invasive prognostic marker for non-small cell lung cancer.
Liu Y; Zhang G; Li H; Han L; Fu A; Zhang N; Zheng Y
Biomed Pharmacother; 2015 Oct; 75():185-90. PubMed ID: 26337230
[TBL] [Abstract][Full Text] [Related]
14. Tyrosine-protein phosphatase non-receptor type 12 expression is a good prognostic factor in resectable non-small cell lung cancer.
Cao X; Chen YZ; Luo RZ; Zhang L; Zhang SL; Zeng J; Jiang YC; Han YJ; Wen ZS
Oncotarget; 2015 May; 6(13):11704-13. PubMed ID: 25868976
[TBL] [Abstract][Full Text] [Related]
15. Development of a patient-centered aggregate score to predict survival after lung resection for non-small cell lung cancer.
Brunelli A; Salati M; Refai M; Xiumé F; Berardi R; Mazzanti P; Pompili C
J Thorac Cardiovasc Surg; 2013 Aug; 146(2):385-90.e1-2. PubMed ID: 23651911
[TBL] [Abstract][Full Text] [Related]
16. Down-regulated microRNA-375 expression as a predictive biomarker in non-small cell lung cancer brain metastasis and its prognostic significance.
Chen LJ; Li XY; Zhao YQ; Liu WJ; Wu HJ; Liu J; Mu XQ; Wu HB
Pathol Res Pract; 2017 Aug; 213(8):882-888. PubMed ID: 28688608
[TBL] [Abstract][Full Text] [Related]
17. Risk factor analysis of locoregional recurrence after sublobar resection in patients with clinical stage IA non-small cell lung cancer.
Koike T; Koike T; Yoshiya K; Tsuchida M; Toyabe S
J Thorac Cardiovasc Surg; 2013 Aug; 146(2):372-8. PubMed ID: 23870323
[TBL] [Abstract][Full Text] [Related]
18. Correlations of lysyl oxidase with MMP2/MMP9 expression and its prognostic value in non-small cell lung cancer.
Liu J; Ping W; Zu Y; Sun W
Int J Clin Exp Pathol; 2014; 7(9):6040-7. PubMed ID: 25337249
[TBL] [Abstract][Full Text] [Related]
19. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
[TBL] [Abstract][Full Text] [Related]
20. Validation of pN2 sub-classifications in patients with pathological stage IIIA N2 non-small cell lung cancer.
Nakagiri T; Sawabata N; Funaki S; Inoue M; Kadota Y; Shintani Y; Okumura M
Interact Cardiovasc Thorac Surg; 2011 May; 12(5):733-8. PubMed ID: 21297135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
